Ferring Pharmaceuticals has acquired the rights to develop and commercialize elobixibat from Albireo, according to a news release. Elobixibat is a compound for chronic idiopathic constipation and ...

The agreement gives Ferring rights to market the product globally with the exception of Japan and a small number of Asian markets. In consideration of the rights, Ferring will pay Albireo a ...

Despite the Ferring drug’s solid data, it wasn't exactly a smooth path to the FDA nod. In May 2020, the FDA rejected the drug, citing outstanding questions for the company’s manufacturing partner.

Elobixibat is due to enter Phase III trials for the CIC indication and Phase IIb for IBS-C shortly. The drug “perfectly complements our gastroenterology portfolio”, said Ferring president Michel ...

Bhavin Vaid Head of Corporate Communications +41 58 301 0952 (direct) +41 79 191 0632 (mobile) [email protected] Lindsey Rodger Senior Manager, Corporate Communications +41 58 451 4023 ...

All registered trademarks above are owned by Ferring B.V. Contact: Rebecca Westelman Burson-Marsteller 212-614-4262 [email protected] References. 1. PREPOPIK™ [Prescribing Information].

Ferring acquires licensing rights for Elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome wit.

The agreement gives Ferring rights to market the product globally with limited exceptions. "Elobixibat perfectly complements our gastroenterology portfolio, which includes PENTASA for IBD and PICOPREP ...